Vimarsana
Biggest News Aggregation in the World

Page 18 - Advanced Solid Tumors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Advanced Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Advanced Solid Tumors Today - Breaking & Trending Today

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with ... - Vimarsana News

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with ... Helsinn Healthcare S.A.January 12, 2021 GMT Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities Lugano, Switzerland, January 12, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first patient has been dosed in a Phase 1/2 Study of TAS095...

Source: apnews.com
Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities - Vimarsana News

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities January 12, 2021 03:30 ET | Source: Helsinn Healthcare S.A. Helsinn Healthcare S.A. Lugano/Pazzallo, SWITZERLAND Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities Lugano, Switzerland, January 12, 2021 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announce...

Helsinn Healthcare S.A.: Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities - Vimarsana News

Helsinn Healthcare S.A.: Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities

(1) Helsinn Announces First Patient Dosed in Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities Lugano, Switzerland, January 12, 2021 - Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease products, today announces the first patient has been dosed in a Phase 1/2 Study of TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities. TAS0953/HM06 is an investigational oral treatment which inhibits several RET abnormalities identified as oncogenic driver alterations in NSCLC, papillary an...

Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering - Vimarsana News

Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering

Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering Nanobiotix will use a portion of the proceeds from the its IPO to launch its global phase III registration study in head and neck cancer in the United States in 2021 Following previously reported preliminary data regarding the ability of NBTXR3 to help transform anti-PD-1 non-responders into responders, the Company will provide the next update on its immuno-oncology phase I basket study evaluating NBTXR3 in combination with anti-PD-1 checkpoint inhibitors in the second quarter of 2021 The ...

Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma - Vimarsana News

Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma

Published: Dec 23, 2020 SAN MATEO, Calif., Dec. 23, 2020 /PRNewswire/ -- Rakuten Medical, Inc. (Rakuten Medical) today announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors (ClinicalTrials.gov Identifier: NCT04305795) has enrolled and treated its first patient in the United States, at The University of Texas MD Anderson Cancer Center, Houston, Texas. Approximately 74 patients are planned for this trial in Head and Neck Squamous Cell Carcinoma (HNSCC) and Cutaneous...